Preserving the Promise™—Together

Cryopreserved cell surrounded by structured ice crystals, representing BioLife Solutions’ focus on protecting cell integrity during freezing and storage.

How BioLife’s Brand Refresh Strengthens the CGT Community Cell and gene therapies (CGTs) are changing what’s possible in medicine. Each vial, batch, and patient represents years of innovation and the hope of a lasting cure. But for these therapies to reach the people who need them, every step must be predictable, reproducible, and protected. That’s […]

Biopreservation Is Critical. Start with the Team That Wrote the Playbook.

Cryogenic storage vial being lifted from a liquid nitrogen tank with forceps, surrounded by vapor, representing precise cell cryopreservation.

Biopreservation in CGT: Expertise that Safeguards Every Cell For developers of cell and gene therapies (CGTs), biopreservation is far more than the simple storage of the product. It impacts various stages of the manufacturing process. The functional viability of cells post-thaw can determine the success of downstream workflows, clinical outcomes, and ultimately, commercial success. To […]

How to prepare early for regulatory submissions from IND to BLA

Early Preparation for IND and BLA Submissions. Illustration of the phases of vaccine clinical trials, showing a progression from preclinical research to Phase 1, Phase 2, Phase 3, and regulatory approval, with icons representing laboratory testing, small and large groups of participants, and final distribution.

Early Preparation for IND and BLA Submissions Bringing a new cell and gene therapy (CGT) to market is a complex journey, and one that requires rigorous testing and adherence to safety and regulatory standards. At BioLife Solutions, we have supported many drug manufacturers as they prepare for Investigational New Drug (IND) and Biologics License Application […]

What COVID Taught Us About the Benefits of Cryopreservation for Cell-Based Therapies

COVID-19 cell illustration

The COVID-19 pandemic significantly impacted various sectors of healthcare, including the blood and biotherapies field. It disrupted the supply and demand for blood and blood-derived cell products, presenting unprecedented logistical challenges that underscored the benefit of cryopreservation for cell and gene therapies (CGT). According to the National Marrow Donor Program (NMDP), cryopreservation of hematopoietic progenitor […]

How the BioLife Solutions Master File Letter Request Process Works for CryoStorĀ® and HypoThermosolĀ® FRS

Gloved hand checks box on regulatory approval

Cross-Referencing BioLife Master Files CryoStor and HypoThermosol FRS (HTS-FRS) are critical components in many customer cell and gene therapy (CGT) and regenerative medicine processes. Although they are not regulated medical products—meaning they are not classified as drugs, medical devices, or marketed/registered as excipients—they serve a critical role as ancillary/raw materials in cell-based manufacturing processes. BioLife […]

This website uses cookies to ensure you get the best experience on our website.